Does Adenomyosis Increase Cancer Risk?

Harald Krentel, Ioannis Vlachodimitris
In: Endometriosis and Adenomyosis · 2022 · pp. 517–522 · doi:10.1007/978-3-030-97236-3_39 · W4285110942
book-chapter OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

Distinguishing endometrial cancer arising from adenomyosis can be clinically challenging and may lead to diagnostic delays, especially in perimenopausal and postmenopausal patients.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text ⓘ

This chapter examines whether adenomyosis increases the risk of endometrial cancer and highlights how endometrial cancer can arise in adenomyotic lesions within the myometrium. It emphasizes a clinical diagnostic challenge in distinguishing true adenomyosis from endometrial cancer associated with adenomyosis versus endometrial cancer coexisting with adenomyotic lesions, which can contribute to delayed diagnosis and potential errors in oncologic staging and surgical decisions. The authors note that adenomyosis itself does not appear to increase endometrial cancer risk overall, but they argue that endometrial cancer related to adenomyosis should be considered as a differential diagnosis in perimenopausal and postmenopausal patients, despite the interpretive difficulty. This paper is centrally about adenomyosis — specifically, whether adenomyosis increases cancer risk and the diagnostic pitfalls when cancer arises within adenomyotic lesions.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 7,251 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Adenomyosis does not seem to increase the risk for endometrial cancer. However, several publications describe endometrial cancer arising from adenomyotic lesions within the myometrial tissue. The differentiation between adenomyosis and endometrial cancer arising from adenomyosis or endometrial cancer coexisting with adenomyotic lesions can be clinically challenging and might lead to a diagnostic delay and erroneous diagnostic and surgical decisions including incorrect oncological staging of endometrial cancer within the myometrial tissue. Especially in perimenopausal and postmenopausal patients, endometrial cancer related to adenomyosis should be considered a possible differential diagnosis to adenomyosis. Access this chapter Tax calculation will be finalised at checkout Purchases are for personal use only Similar content being viewed by others Change history 10 September 2022 Correction to:

References

Raffone A, Seracchioli R, Raimondo D, Maletta M, Travaglino A, Raimondo I, Giaquinto I, Orsini B, Insabato L, Pellicano M, Zullo F. Prevalence of adenomyosis in endometrial cancer patients: a systematic review and meta-analysis. Arch Gynecol Obstet. 2020. https://doi.org/10.1007/s00404-020-05840-8. Epub ahead of print. PMID: 33098006. Habiba M, Pluchino N, Petignat P, Bianchi P, Brosens IA, Benagiano G. Adenomyosis and endometrial cancer: literature review. Gynecol Obstet Investig. 2018;83(4):313–28. https://doi.org/10.1159/000487320. Epub 2018 Jun 6. PMID: 29874641. Rubod C, Narducci F, Delattre C, Decocq J, Verbert A, Delahousse G. Adénocarcinome endométrioïde résultant de foyers d’adénomyose: à propos d’un cas et revue de la littérature [Endometrioid adenocarcinoma arising from adenomyosis. A case report and literature review]. J Gynecol Obstet Biol Reprod (Paris). 2004;33(2):140–4. https://doi.org/10.1016/s0368-2315(04)96413-7. French. PMID: 15052180. Kazandi M, Zeybek B, Terek MC, Zekioglu O, Ozdemir N, Oztekin K. Grade 2 endometrioid adenocarcinoma arising from adenomyosis of the uterus: report of a case. Eur J Gynaecol Oncol. 2010;31(6):719–21. PMID: 21319528. Boes AS, Tousseyn T, Vandenput I, Timmerman D, Vergote I, Moerman P, Amant F. Pitfall in the diagnosis of endometrial cancer: case report of an endometrioid adenocarcinoma arising from uterine adenomyosis. Eur J Gynaecol Oncol. 2011;32(4):431–4. PMID: 21941970. Kucera E, Hejda V, Dankovcik R, Valha P, Dudas M, Feyereisl J. Malignant changes in adenomyosis in patients with endometrioid adenocarcinoma. Eur J Gynaecol Oncol. 2011;32(2):182–4. PMID: 21614909. Machida H, Maeda M, Cahoon SS, Scannell CA, Garcia-Sayre J, Roman LD, Matsuo K. Endometrial cancer arising in adenomyosis versus endometrial cancer coexisting with adenomyosis: are these two different entities? Arch Gynecol Obstet. 2017;295(6):1459–68. https://doi.org/10.1007/s00404-017-4375-z. Epub 2017 Apr 25 Yuan H, Zhang S. Malignant transformation of adenomyosis: literature review and meta-analysis. Arch Gynecol Obstet. 2019;299(1):47–53. https://doi.org/10.1007/s00404-018-4991-2. Epub 2018 Dec 5. PMID: 30519753. Kossaï M, Penault-Llorca F. Role of hormones in common benign uterine lesions: endometrial polyps, leiomyomas, and adenomyosis. Adv Exp Med Biol. 2020;1242:37–58. https://doi.org/10.1007/978-3-030-38474-6_3. PMID: 32406027. Benagiano G, Brosens I, Habiba M. Adenomyosis: a life-cycle approach. Reprod Biomed Online. 2015;30(3):220–32. https://doi.org/10.1016/j.rbmo.2014.11.005. Epub 2014 Nov 20. PMID: 25599903. Matsuo K, Moeini A, Machida H, Scannell CA, Casabar JK, Kakuda M, Adachi S, Garcia-Sayre J, Ueda Y, Roman LD. Tumor characteristics and survival outcome of endometrial cancer arising in adenomyosis: an exploratory analysis. Ann Surg Oncol. 2016;23(3):959–67. https://doi.org/10.1245/s10434-015-4952-y. Epub 2015 Nov 5. PMID: 26542589; PMCID: PMC7521605. Honda M, Tsuchiya A, Isono W, Takahashi M, Fujimoto A, Kawamoto M, Nishii O. Endophytic-type endometrial cancer with adenomyosis successfully diagnosed with hysteroscopic endometrial biopsy using an 8.3-mm operative resectoscope: a case report. Case Rep Oncol. 2018;11(2):311–7. https://doi.org/10.1159/000489084. PMID: 29928209; PMCID: PMC6006659. Li Y, Lin CY, Qi YF, Wang XQ, Chen B, Zhou HL, Ren J, Yang JJ, Xiang Y, He YL, Xue HD, Jin ZY. Non-invasive differentiation of endometrial adenocarcinoma from benign lesions in the uterus by utilization of amide proton transfer-weighted MRI. Mol Imaging Biol. 2021;23(3):446–55. https://doi.org/10.1007/s11307-020-01565-x. Epub 2020 Nov 13. PMID: 33185840. Khalifa MA, Atri M, Klein ME, Ghatak S, Murugan P. Adenomyosis as a confounder to accurate endometrial cancer staging. Semin Ultrasound CT MR. 2019;40(4):358–63. https://doi.org/10.1053/j.sult.2019.04.004. Epub 2019 Apr 18. PMID: 31375175. Taneichi A, Fujiwara H, Takahashi Y, Takei Y, Machida S, Saga Y, Takahashi S, Suzuki M. Influences of uterine adenomyosis on muscle invasion and prognosis of endometrioid adenocarcinoma. Int J Gynecol Cancer. 2014;24(8):1429–33. https://doi.org/10.1097/IGC.0000000000000243. PMID: 25188882. Ismiil N, Rasty G, Ghorab Z, Nofech-Mozes S, Bernardini M, Ackerman I, Thomas G, Covens A, Khalifa MA. Adenomyosis involved by endometrial adenocarcinoma is a significant risk factor for deep myometrial invasion. Ann Diagn Pathol. 2007;11(4):252–7. https://doi.org/10.1016/j.anndiagpath.2006.08.011. PMID: 17630108. Aslan K, Sarı ME, Yalçın HR, Yalçın İ, Cüylan ZF, Özdal B. Coexistence of uterine adenomyosis is not associated with a better prognosis in endometrioid-type endometrial cancer. Ir J Med Sci. 2020;189(3):835–42. https://doi.org/10.1007/s11845-020-02172-z. Epub 2020 Jan 23. PMID: 31970616. Chao X, Wu M, Ma S, Tan X, Zhong S, Bi Y, Wu H, Lang J, Li L. The clinicopathological characteristics and survival outcomes of endometrial carcinoma coexisting with or arising in adenomyosis: a pilot study. Sci Rep. 2020;10(1):5984. https://doi.org/10.1038/s41598-020-63065-w. PMID: 32249826; PMCID: PMC7136226. Erkilinç S, Taylan E, Gülseren V, Erkilinç G, Karadeniz T, Bağci M, Temel O, Solmaz U, Gökçü M, Sanci M. The effect of adenomyosis in myometrial invasion and overall survival in endometrial cancer. Int J Gynecol Cancer. 2018;28(1):145–51. https://doi.org/10.1097/IGC.0000000000001137. PMID: 29040186. An M, Duan H, Zhang Y. Prognostic significance of co-existent adenomyosis on outcomes and tumor characteristics of endometrial cancer: a meta-analysis. J Obstet Gynaecol Res. 2020;46(9):1851–63. https://doi.org/10.1111/jog.14371. Epub 2020 Jul 19. PMID: 32686169. Author information Authors and Affiliations Corresponding author Editor information Editors and Affiliations Rights and permissions Copyright information © 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG About this chapter Cite this chapter Krentel, H., Vlachodimitris, I. (2022). Does Adenomyosis Increase Cancer Risk?. In: Oral, E. (eds) Endometriosis and Adenomyosis. Springer, Cham. https://doi.org/10.1007/978-3-030-97236-3_39 Download citation DOI: https://doi.org/10.1007/978-3-030-97236-3_39 Published: Publisher Name: Springer, Cham Print ISBN: 978-3-030-97235-6 Online ISBN: 978-3-030-97236-3 eBook Packages: MedicineMedicine (R0)

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK